In this section you will find older BSP UK press releases from over the last year.
If you have a particular enquiry about any of these releases then please contact us on the telephone number or e-mail address below:-
Tel: 01635 563198
6th December 2009
Data from a Phase III trial of an oral anticoagulant in the chronic setting demonstrates that Bayer’s oral anticoagulant Xarelto reduces the risk of potentially fatal recurring venous blood clots by 82%.
>>more
3rd December 2009
Bayer Healthcare today submitted its appeal to NICE, contesting the institute’s Final Appraisal Determination (FAD) to deny patients with advanced hepatocellular carcinoma (HCC), the commonest form of primary liver cancer, NHS funding for Nexavar® (sorafenib).
>>more
30th November 2009
Development of PET tracer florbetaben for beta-amyloid imaging in patients with Alzheimer’s disease is progressing as planned
>>more
19 November, 2009
Bayer Healthcare today confirmed that it is to appeal the decision by NICE to deny NHS funding for Nexavar® (sorafenib), a treatment for a type of primary liver cancer known as advanced hepatocellular carcinoma (HCC).
12th October 2009
Florbetaben will be used for the very first time in Alzheimer’s patients being treated with a vaccination therapy
>>more
09 October, 2009
Bayer Schering Pharma’s Qlaira, the unique oral contraceptive containing estradiol valerate/dienogest, significantly reduced menstrual blood loss (MBL) in a new clinical study with women suffering from heavy and/or prolonged menstrual bleeding without organic pathology.
>>more
28th September 2009
Men across the UK are being urged to ‘Revive Your Drive’ following the launch of a new campaign to raise awareness of Testosterone Deficiency Syndrome (TDS).
>>more
21st July 2009
The anticipated National Institute for Health and Clinical Excellence (NICE) decision on the Final Appraisal Determination (FAD) for Nexavar® (sorafenib) for the treatment of advanced hepatocellular carcinoma (HCC) has been delayed, to allow consideration of the patient access scheme, Bayer Schering Pharma has agreed with the Department of Health>>more
20th July 2009
Dr. Luis Felipe Graterol has taken on the role of Medical Director at Bayer Schering Pharma (BSP) UK. >>more
8th June 2009
New combined oral contraceptive pill offers more choice to meet the individual needs of women today. >>more
19th May 2009
Positive data from a phase II trial with Bayer Schering Pharma’s oral agent riociguat for the treatment of two different forms of pulmonary hypertension (PH); chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH); were presented today at the American Thoracic Society (ATS) international conference in San Diego, USA. >>more
6th May 2009
Patients denied chance for extra time with family and loved ones after initial refusal to fund first systemic therapy proven to extend overall survival.>>more
28th April 2009
Today the National Institute for Health and Clinical Excellence (NICE) announced the Final Appraisal Determination (FAD) for Nexavar® (sorafenib), Sutent® (sunitinib), Avastin® (bevacizumab) and Torisel® (temsirolimus) in advanced kidney cancer. NICE has not recommended sorafenib, bevacizumab and temsirolimus as first line treatment option for kidney cancer. Furthermore, it does not recommend sorafenib or sunitinib for second line treatment for renal cell carcinoma (RCC) patients.>>more
23rd April 2009
The first ever UK TV advertisement campaign for emergency contraceptive pill (ECP), Levonelle® One Step, launches today.>>more
22nd April 2009
Without preventative treatment, 45,000 people undergoing elective hip or knee replacement every year in England could develop a potentially fatal blood clot. NICE now recommends Xarelto® – a new, oral anticoagulant, up to 70% more effective at reducing blood clots than the current gold standard (injectable enoxaparin).>>more
31st March 2009
Bayer Schering Pharma (BSP), (the prescription medicines arm of Bayer HealthCare in the UK) is to distribute selected products (BSP Products) under a new reduced wholesaler model, with Alliance Healthcare (Distribution) Limited (UniChem), Phoenix Healthcare Distribution Limited and AAH Pharmaceuticals Limited, effective from 1st July 2009. >>more
9th March 2009
The SMC has today accepted Nebido® (testosterone undecanoate) for use in Scotland for the treatment of hypogonadism, also known as Testosterone Deficiency Syndrome (TDS), when testosterone deficiency has been confirmed by clinical features and biochemical tests.>>more
4th March 2009
The National Institute for Health and Clinical Excellence (NICE) has issued an initial positive opinion on the new oral anticoagulant Xarelto® for the prevention of potentially fatal blood clots after elective hip or knee replacement surgery.>>more
18th February 2009
Based on the positive findings of the clinical development phase II trial, Bayer Schering Pharma has received ethical approval from the Cambridgeshire 1 Research Ethics Committee in the United Kingdom to begin the phase III program for its oral agent riociguat.>>more
